Surmodics drug delivery coatings span both durable and biodegradable polymer systems, with the formulation expertise to match the right matrix to the drug, the device, and the clinical indication. Our coating platforms are backed by decades of pre-clinical and clinical use, including the first-to-market drug-eluting coronary stent, with the regulatory experience and analytical depth to bring drug-device combinations through approval.
Sustained drug delivery with tailorable elution profiles from minutes to years.
Durable and bioresorbable polymer technologies for short to long term drug delivery.
Control over drug solid form, an important formulation parameter to ensure product consistency.
Delivery capabilities include the full range of therapeutic compounds, including small molecular weight hydrophilic and hydrophobic APIs, and large molecular weight biologics.
Includes:
Includes:
Surmodics drug delivery coatings are used across the medical device categories where targeted, sustained, or controlled drug release shapes clinical outcomes.
Hydrocephalic shunts and other neurological devices where local drug delivery shapes clinical performance.
Coronary stent systems, drug-eluting stents, and drug-coated balloons for cardiovascular indications, including the first-to-market drug-eluting coronary stent platform.
CRT leads and pacemaker leads where local anti-inflammatory, or anti-fibrotic delivery supports long-term performance.
Drug-coated balloons, peripheral stents, and vascular closure devices for peripheral vascular intervention.
Intravitreal implants, glaucoma devices, and access instruments for sustained release of steroids and other therapeutic agents.
Stents, catheters, contraceptive systems, and penile implants where sustained or targeted drug release supports clinical use.
Implantable sensors where targeted drug release shapes signal integrity, biocompatibility, and device longevity.
Surmodics SundanceDCB (3 µg/mm2) vs. Competitor Reported Studies
Surmodics sirolimus DCB unique and differentiated PK profile
PP Poplulation
The Sundance sirolimus DCB demonstrated 84% patency, sustained through 24 months in the SWING clinical trial
“These studies appear to show very promising preclinical results for the Sundance DCB. With sustained drug release through 90 days, this novel device should result in good short and long-term clinical outcomes.” - Dr. Aloke Finn
Drug delivery coatings are only part of the answer. The companies that bring better drug-device combinations to market faster are the ones working with a partner that brings polymer science, regulatory experience, and manufacturing scale to the same conversation.
Durable or bioresorbable drug delivery coating systems with tunable elution kinetics, developed and clinically validated across stents, balloons, implants, and access devices.
Coating science engaged from feasibility through post-launch support, with the regulatory and quality infrastructure to back every phase of a drug-device combination program.
Formulations configured to the drug, the device, the target tissue, and the regulatory pathway.
High-capacity manufacturing, the largest clinical data set in the drug-eluting stent category, and almost 50 years of operational maturity behind every program.
Whether you are evaluating polymer matrix options at feasibility, characterizing elution profiles in development, or scaling toward commercial launch of a drug-device combination, Surmodics is built to engage at any stage of the program.
*Data on file
SURMODICS, PRESIDE, PHOTOLINK, HYDROBOND, TRANSCEND, SURVEIL, SUNDANCE and the SURMODICS logo are trademarks of Surmodics Inc. and/or it's affiliates. All other trademarks are trademarks of their respective owners. © 2026 Surmodics, Inc. All rights reserved. SRDX015 06/26
